Literature DB >> 3501471

Changes in circulating monocytes in patients with progressive systemic sclerosis.

B S Andrews1, G J Friou, M A Berman, C I Sandborg, G R Mirick, T C Cesario.   

Abstract

Circulating monocytes in 30 patients with progressive systemic sclerosis (PSS, scleroderma) and 28 age and sex matched normal controls were studied. Binding of the lectin peanut agglutinin (PA) was significantly reduced in PSS monocytes (p less than 0.001) together with a reduction in the density of nonspecific esterase staining (p less than 0.001) suggesting advanced maturation. Using monoclonal antibodies to identify cell surface markers, we demonstrated a significant reduction in PSS monocytes bearing the Leu M2 antigen (Mac 120, antigen presenting cells) over controls (p less than 0.05), but were unable to show any differences in the monocyte subpopulations using antisera against Leu M3 and HLA-DR surface antigens. The ectoenzymes 5'-nucleotidase (5'N) and alkaline phosphodiesterase 1 (APD1) were lower and leucine aminopeptidase (LAP) levels were higher in patients with PSS, compatible with immune activation. Interferon-gamma levels in serum did not appear to account for these changes, whereas the levels of Clq binding complexes correlated inversely with the levels of LAP (p less than 0.05). There was a strong correlation between the number of Leu M3 positive cells and the level of the ectoenzyme LAP (p less than 0.001). With increasing disease duration, higher levels of Clq binding complexes were detected (p less than 0.05). These results indicate that monocytes in PSS differ from those in normals and appear to have undergone advanced differentiation and activation changes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501471

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

2.  In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases.

Authors:  C Prior; P L Haslam
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.

Authors:  C J Carrera; C Terai; M Lotz; J G Curd; L D Piro; E Beutler; D A Carson
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.

Authors:  Nobuyo Higashi-Kuwata; Masatoshi Jinnin; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Faith C Muchemwa; Yuji Yonemura; Yoshihiro Komohara; Motohiro Takeya; Hiroaki Mitsuya; Hironobu Ihn
Journal:  Arthritis Res Ther       Date:  2010-07-05       Impact factor: 5.156

5.  Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.

Authors:  Sarah A Pendergrass; Everett Hayes; Giuseppina Farina; Raphael Lemaire; Harrison W Farber; Michael L Whitfield; Robert Lafyatis
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

6.  The vascular microenvironment and systemic sclerosis.

Authors:  Tracy Frech; Nathan Hatton; Boaz Markewitz; Mary Beth Scholand; Richard Cawthon; Amit Patel; Allen Sawitzke
Journal:  Int J Rheumatol       Date:  2010-08-10

Review 7.  The role of type 1 interferon in systemic sclerosis.

Authors:  Minghua Wu; Shervin Assassi
Journal:  Front Immunol       Date:  2013-09-06       Impact factor: 7.561

Review 8.  The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.

Authors:  Rob J W Arts; Leo A B Joosten; Mihai G Netea
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.